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Abstract: Japanese cedar pollen is the most common causative
allergen for seasonal allergic rhinitis (AR) in Japan. More commonly
known as Japanese cedar pollinosis, it occurs in spring causing the
typical symptoms of seasonal AR, such as sneezing, rhinorrhea,
nasal obstruction, nasal itching, and itching of the eyes. Previous
reports indicate that the prevalence of Japanese cedar pollinosis
among Japanese was 26.5%. According to a more recent question-
naire-based survey, the prevalence of Japanese cedar pollinosis in
patients with adult asthma might be up to 30% to 50%, suggesting
higher rates than that previously reported. Moreover, 30% to 60% of
adult asthmatic patients with concomitant pollinosis have exacer-
bations of their asthma symptoms during the Japanese cedar pollen
season. These ﬁndings suggest that concomitant Japanese cedar
pollinosis may be an aggravating factor in patients with asthma. As
with other pollens, such as grass and birch, Japanese cedar pollen
was shown to be a trigger factor for worsening asthma. In clinical
practice, a number of Japanese patients with asthma are mono-
sensitized to Japanese cedar pollen but not to other antigens. Further
studies are needed to elucidate the mechanisms of Japanese cedar
pollen in inducing and in exacerbating asthma. The presence of
concomitant AR is often associated with the difﬁculty in asthma
control. However, there has been a controversy whether treating
concomitant AR by intranasal corticosteroid would produce better
asthma-related outcomes in patients with asthma and AR. The effect
of treating concomitant cedar pollinosis by intranasal corticosteroids
on asthma control in patients with asthma and cedar pollinosis also
remains unknown. Certain systemic treatments, such as leukotriene
receptor antagonist and anti-IgE monoclonal antibody, are supposed
to reduce the symptoms of both asthma and AR in patients with
asthma and concomitant AR. In conclusion, Japanese cedar pollino-
sis is often associated with exacerbations of asthma. Further
investigations are expected to elucidate the precise impact and
mechanisms of Japanese cedar pollinosis in asthma.
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ASTHMA AND JAPANESE POLLINOSIS
Japanese cedar pollen is the most common allergen, whichelicits seasonal allergic rhinitis (AR) in spring, in Japan. An
alarming number of the patients with Japanese cedar pollinosis
suffer from symptoms, such as rhinorrhea, nasal obstruction,
nasal itching, sneezing, and itching of the eyes. According to
the survey based on a questionnaire, the prevalence of AR and
Japanese cedar pollinosis was 23.4% and 26.5%, respectively,
in Japan.1 In recent years, Japanese cedar pollinosis is called
as “a folk disease” in Japan, due to the increase in the number
of patients and increase of the related medical costs. In addi-
tion, lowering trend in the age of patients with Japanese cedar
pollinosis has been noted in recent years. Prevalence rate of
Japanese cedar pollinosis in children was reported to be
13.8% to 22.9%.2 This survey was executed in 407 to 510
children in May or June every year from 1995 to 2001. Prev-
alence rate of pollinosis was found to be related to the amount
of pollen in the air. The amount of pollen in the air differs by
the area and the year. Okamoto3 reported that 60% of ele-
mentary school students in Yamanashi prefecture, who had
been exposed to high amounts of pollen, showed high levels
of speciﬁc IgE antibodies to Japanese cedar pollen in sera.
AR and asthma frequently coexist. In previous reports,
30% to 40% of the patients with AR were found to have
concomitant asthma, and 50% to 80% of the patients with
asthma had concomitant AR.4 A large-scale epidemiological
survey in Tohoku area was reported in 2009 by Yamauchi
et al.5 In this survey, 6064 patients with asthma and 3945
patients with AR were enrolled. Of 2781 patients with adult
asthma, 1693 (60.8%) patients had AR symptoms, and 1155
(41.5% in 2781) patients were eventually diagnosed with AR.
Likewise, among 3283 patients with childhood asthma, 1335
(40.6%) patients were eventually diagnosed with AR. Mean-
while, 49.0% of 3945 patients with AR showed asthmatic
symptoms and 34.8% (in 3945) were eventually diagnosed
with asthma, suggesting the high prevalence of asthma in
patients with AR.
Prevalence of AR in atopic asthmatic patients is higher
than that in nonasthmatic patients. Likewise, in clinical
practice, the patients with asthma are often associated with
Japanese cedar pollinosis; in addition, the patients with
asthma and concomitant Japanese cedar pollinosis often show
exacerbation in the season of Japanese cedar pollen. There-
fore, we investigated the prevalence of concomitant asthma
and Japanese cedar pollinosis, and the impact of Japanese
cedar pollinosis on asthmatic control in 333 patients with
adult asthma.5 Overall, 333 asthmatic patients, whose mean
age was 48.3 6 1.0 years and ranged from 15 to 83 years,
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were enrolled in the study (137 males and 196 females). The
prevalence of Japanese cedar pollinosis was 34.8% (116
patients). Patients’ characteristics are shown in Table 1.
Distribution of the population classiﬁed by severity was sim-
ilar between the groups with and without cedar pollinosis
(Table 1). Asthmatic patients with Japanese cedar pollinosis
were found across all age groups (Fig. 1). Among 116 asth-
matic patients with Japanese cedar pollinosis, 41 (35.3%)
patients reported that their asthmatic control was aggravated
during Japanese cedar pollen season. Among 41 patients
whose asthma was well controlled, but was aggravated during
the Japanese cedar pollen season, 13 patients showed a
decrease in morning peak expiratory ﬂow more than 10%
during Japanese cedar pollen season compared with the base-
line values (Fig. 2). However, it should be taken into account
that the effect of virus infection, the most potent inducer of
TABLE 1. Patient Characteristics
Total Cedar Pollinosis (2) Cedar Pollinosis (1)
No. patients 333 217 116
Age, yr 48.3 6 1.0 48.7 6 1.3 47.5 6 1.6
Sex, n (%)
Male 137 (41.1) 91 (41.9) 46 (39.7)
Female 196 (58.9) 126 (58.1) 70 (60.3)
Type Atopic, n (%) 211 (63.4) 129 (59.5) 82 (70.7)
Nonatopic 122 (36.6) 88 (40.5) 34 (29.3)
Duration of asthma, yr 15.3 6 0.8 15.0 6 1.0 15.8 6 1.3
IgE RIST (U/mL) 565.8 6 51.6 580.6 6 72.9 538.9 6 60.3
Cedar RAST (UA/mL) 10.9 6 1.4 4.2 6 1.2 23.4 6 2.8
Histamine-PC20 (mg/mL) 1424 6 194 (n ¼ 125) 1550 6 262 (n ¼ 81) 1193 6 267 (n ¼ 44)
Severity of asthma, n (%)
Mild 81 (24.3) 54 (24.9) 27 (23.3)
Moderate 177 (53.2) 116 (53.5) 61 (52.6)
Severe 75 (22.5) 47 (21.6) 28 (24.1)
Therapy, n (%)
BDP 275 (82.6) 182 (83.9) 93 (80.2)
Slow-release theophylline 259 (77.8) 165 (76.0) 94 (81.0)
Oral b2-agonists 126 (37.8) 77 (35.5) 49 (42.2)
Anti-allergic agents, n (%) 57 (17.1) 37 (17.1) 20 (17.2)
Oral steroids, n (%) 20 (6.0) 13 (6.0) 7 (6.0)
Adapted from Ueno et al (2002) with permission from Arerugi.6
RIST, Radio ImmunoSorbent Test; RAST, Radio AllergoSorbent Test.
FIGURE 1. Distribution of the age of patients with asthma
with or without complication with Japanese cedar pollinosis.
Number of the patients was demonstrated. Adapted from
Ueno et al (2002) with permission from Arerugi.6
FIGURE 2. Number of patients whose morning peak
expiratory flow decreased more or less than 10% compared
with the baseline values was demonstrated. Adapted from
Ueno et al (2002) with permission from Arerugi.6
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asthma exacerbation, was not ruled out in this study. Next,
we compared the patients’ characteristics between the group
that had and the group that did not have exacerbation of their
asthma symptoms during Japanese cedar pollen season
(Table 2). Among 116 asthmatic patients with Japanese cedar
pollinosis, airway hyperresponsiveness was determined in 44
patients before the season of Japanese cedar pollen. Although
the level of histamine-PC20 in the group in which asthmatic
symptoms were exacerbated was lower than that in the group
in which asthmatic symptoms were not exacerbated, they did
not show statistical signiﬁcance. Total IgE levels and speciﬁc
IgE levels to Japanese cedar pollen showed no signiﬁcant
difference between the 2 groups.
According to the article reported by Fukushi et al,6 the
prevalence of Japanese cedar pollinosis in 151 patients with
asthma was 47.0%, and 54.9% of the asthmatic patients
with concomitant Japanese cedar pollinosis was associated
with aggravation of asthma symptoms and reduced asthma
control during Japanese cedar pollen season. These research-
ers also showed that the asthmatic patients with concomitant
Japanese cedar pollinosis had lower levels of peak expiratory
ﬂow during the Japanese cedar pollen season.
These reports including ours suggest that the prevalence
of Japanese cedar pollinosis in patients with adult asthma
might be 30% to 50%, and 30% to 60% of adult asthmatic
patients with concomitant pollinosis might be associated with
exacerbation of asthma during Japanese cedar pollen season.
However, it is noteworthy that the diagnosis of Japanese
cedar pollinosis is sometimes difﬁcult, and the prevalence of
Japanese cedar pollinosis has been changed decade by decade
and by the area.
HYPOTHETIC MECHANISMS OF JAPANESE
CEDAR POLIINOSIS–INDUCED
ASTHMA EXACERBATIONS
Grass and birch pollens are well known to induce
asthma in Western countries. On the contrary, Japanese cedar
pollen had not been thought to elicit asthma because the
diameter of Japanese cedar pollen is approximately 30 mm
that is not thought to be able to reach to lower airways. How-
ever, Maeda et al7 reported that asthma can be provoked by
Japanese cedar pollen. The asthmatic patients whose asthma
symptoms were induced by Japanese cedar pollen developed
the symptoms during the cedar pollen season. Among the 6
asthmatic patients whose asthma was induced by Japanese
cedar pollen, 5 patients suffered from cedar pollinosis in
addition to asthma and 1 patient had no pollinosis. In clinical
practice, a number of patients with asthma are sensitized only
to Japanese cedar pollen but not to other major antigens (mite,
house dust, grass and birch pollens, fungus, and any pets). In
these cases, patients usually get classiﬁed as nonatopic
asthma. Instead, one should take into account that Japanese
cedar pollen can cause asthma symptoms in these patients.
As shown above, Japanese cedar pollen is associated
with exacerbations of asthma in a number of patients. Few
reports have elucidated the mechanisms of how Japanese
cedar pollen induces asthma exacerbations in patients with
asthma with comorbid Japanese cedar pollinosis. On the
contrary, there are many reports that elucidated how perennial
AR is associated with exacerbation of asthma.8,9 Therefore,
hypothetic mechanisms on how Japanese cedar pollen indu-
ces exacerbation in patients with asthma can be considered to
be based on the mechanisms of AR-exacerbated asthma.
Patients with asthma and concomitant pollinosis have a nasal
obstruction during Japanese cedar pollen season, resulting in
difﬁculty in nasal breathing. One of the most important nasal
functions is trapping of environmental antigen, such as house
dust and Japanese cedar pollen. Eventually, the absence of
nasal trapping may facilitate the incursion of environmental
antigen, resulting in the exacerbation of asthma. Moreover,
insufﬁciency of humidity control and temperature control,
resulting from nasal obstruction during Japanese cedar pollen
season, is also considered to be associated with exacerbation
of asthma. Furthermore, the direct impact of upregulated
cytokines and chemokines from the upper airway to the lower
airway and the systemic link also play a crucial role.
Both AR and asthma exhibit a similar pathophysiologic
ﬁnding in upper and lower airways, respectively. They share
similar ﬁndings of chronic inﬂammation with eosinophils,
lymphocytes, macrophages, mast cells, cytokines, leukotrienes,
and other inﬂammatory mediators10 (Fig. 3). It is thought that
there may be more patients who potentially have comorbidity
of AR and asthma than is reported previously because studies
have demonstrated the presence of eosinophils in the upper
airways of patients with asthma without nasal symptoms and
the presence of eosinophils in the lower airways of patients
with AR who do not exhibit bronchial hyperreactivity or other
asthmatic symptoms.11,12 A potential mechanism linking AR
and asthma is a systemic inﬂammatory response to allergen.
Braunstahl et al13 reported that eosinophilic inﬂammation was
TABLE 2. Patient Characteristics on Exacerbation During
Japanese Cedar Pollen Season
Exacerbation (1) Exacerbation (2)
No. patients 41 75
Age, yr 49.5 6 2.9 46.5 6 1.9
Sex, n (%)
Male 16 (39.0) 30 (40.0)
Female 25 (61.0) 45 (60.0)
Type Atopic, n (%) 31 (75.6) 51 (68.0)
Nonatopic 10 (24.4) 24 (32.0)
Duration of asthma, yr 16.8 6 2.2 15.2 6 1.6
IgE RIST (U/mL) 532.2 6 101.1 542.7 6 75.7
Cedar RAST (UA/mL) 25.1 6 5.5 22.4 6 8.1
Histamine-PC20 (mg/mL) 841 6 288 (n ¼ 15) 1375 6 886 (n ¼ 29)
Severity of asthma, n (%)
Mild 6 (14.6) 21 (28.0)
Moderate 22 (53.7) 39 (52.0)
Severe 13 (31.7) 15 (20.0)
Therapy, n (%)
BDP 34 (82.9) 59 (78.7)
Slow-release theophylline 37 (90.2) 57 (76.0)
Oral b2-agonists 21 (51.2) 28 (37.3)
Anti-allergic agents, n (%) 5 (12.2) 14 (18.7)
Oral steroids, n (%) 2 (4.9) 4 (5.3)
Adapted from Ueno et al (2002) with permission from Arerugi.6
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increased in lower airways of patients with seasonal AR,
24 hours after nasal allergen challenge. Moreover, eosinophilic
inﬂammation was enhanced by the segmental endobronchial
allergen challenge with grass pollen in the nasal lamina
propria and nasal epithelium of atopic subjects.14 These ﬁnd-
ings suggest a cross talk between allergic nasal inﬂammation
and allergic lower airway inﬂammation, and the presence
of more AR patients who have the potential of developing
asthma and more asthmatic patients who have the potential
of developing AR.
An early study suggested that a nasobronchial reﬂex arc
would contribute to the linking of AR and asthma.15 Based on
this hypothesis, nasal allergen challenge affects bronchial
hyperresponsiveness through a reﬂex arc that involves trigem-
inal afferents and vagal efferents.
TREATMENT STRATEGY OF ASTHMA WITH
COMORBID AR OR JAPANESE
CEDAR POLLINOSIS
It is well known that the diagnosis of AR often precedes
that of asthma.16 Rhinitis is an independent risk factor, intrigu-
ingly, not only in atopic individuals but also in nonatopic
individuals for the subsequent development of asthma.17
Therefore, early intervention treatment of AR is hopefully
considered as a preventive therapy for asthma. In fact, the
Preventive Allergy Treatment study demonstrated that contin-
uous pollen-speciﬁc immunotherapy for 3 years decreased the
occurrence of asthma in patients with AR compared with that
in patients with AR not receiving the immunotherapy.18 How-
ever, whether Japanese cedar pollinosis precedes asthma is still
unknown.
The presence of concomitant AR is often associated
with the difﬁculty of asthma control.19 In fact, here, we
showed that AR increased the risk of asthma attacks and
emergency room visit (Fig. 4).20 This leads to the question
whether treating concomitant AR would produce better
asthma-related outcomes in addition to the obvious beneﬁts
with regard to nasal symptoms. Studies have produced con-
ﬂicting results regarding the effects of intranasal
corticosteroids on the lower airways of patients with AR.
Some of these studies21,22 have shown decreased bronchial
hyperresponsiveness after treatment with intranasal cortico-
steroids, whereas other studies23,24 failed to show this. One
study reported the positive effects of intranasal corticosteroids
on the symptoms of asthma but not on bronchial responsive-
ness.25 The reason of this controversy has not been elucidated
yet. However, at least, the differences of study designs and
patient characteristics, including age and the concomitant
presence or absence of asthma, are considered to be asso-
ciated with this controversy. Despite the fact that intranasal
steroids are the most effective agents for controlling
symptoms of AR, second-generation antihistamines are
still regarded as the ﬁrst-line therapy for especially mild-to-
moderate AR. Although antihistamines are not considered an
effective treatment for asthma, Grant et al26 reported that an
oral antihistamine given to patients with concomitant AR and
asthma could improve persistent asthma symptoms during
pollen season.
FIGURE 3. Mechanisms of
allergic inflammation. Adapted
from Holgate (2008) with
permission from Clin Exp
Allergy.11
FIGURE 4. Asthma-related resource use and asthma attacks
according to the presence of concomitant AR (% patients). h,
asthma; n, asthma with AR. Adapted from Bousquet et al (2005 )
with permission from Clin Exp Allergy.21
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Leukotrienes are involved in the mechanisms of both
asthma and AR. Therefore, leukotriene receptor antagonist
(LTRA) is an effective drug for the patients with asthma and
AR. In fact, COMPACT study (Clinical Outcomes with
Montelukast as a Partner Agent to Corticosteroid Therapy)
showed that LTRA was more effective in patients with
asthma and AR than in those with asthma alone.27 Sagara
et al28 demonstrated that a number of the patients with Japa-
nese cedar pollinosis but not with asthma showed an increase
in airway hyperresponsiveness during pollen season. They
also demonstrated that this increase was inhibited by LTRA.
Omalizumab, a humanized monoclonal anti-IgE antibody, is
a novel drug for patients with severe asthma. The mechanism
of omalizumab is inhibition of the binding of IgE to FceRI on
mast cells and basophils. The effectiveness of omalizumab on
AR and Japanese cedar pollinosis was demonstrated as well
as on asthma.29,30 These data suggest that certain systemic
drugs such as LTRAs and anti-IgE monoclonal antibody
would produce better asthma-related outcomes in patients
with asthma and concomitant AR.
CONCLUSIONS
There is a high prevalence of Japanese cedar pollinosis
in patients with asthma. Concomitant Japanese cedar polli-
nosis is regarded as one of the factors leading to asthma
exacerbations in patients with asthma and cedar pollinosis.
Therefore, treatment of cedar pollinosis may contribute to
better asthma control.
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